Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
French news today
Increase in the sale of substitution treatments
Some customers have changed their habits. " I consume fewer cigarettes, before I was almost a pack a day, now I select the times when I smoke, " says a young smoker. " I buy packs of 20 instead of taking packs of 25, " says another client. The display of electronic cigarettes is more and more recipe. The sale of substitution treatments is on the rise: 2.7 million months of treatment were sold in 2017, compared to 1.9 million in 2008. A trend accelerated by a better reimbursement. The cost of antitobacco treatment has exceeded 20 million euros, compared to 11 million in 2016. For the Alliance against smoking,
https://translate.google.com/translate?hl=en&sl=fr&u=https://fr.news.yahoo.com/tabac-chute-livraisons-aupr%25C3%25A8s-d%25C3%25A9bitants-141149993.html&prev=search
In France...
The rise in cigarette pack prices is already having some repercussions. Between falling sales and increasing use of nicotine substitutes , the government's anti-smoking plan is paying off.
https://translate.google.com/translate?hl=en&sl=fr&u=https://www.assurland.com/assurance-blog/assurance-sante-actualite/une-chute-des-ventes-de-tabac-suite-a-la-hausse-des-prix_130940.html&prev=search
Was watching my daily french news last night and they were saying that people are starting to smoke less due to the price increase and they are
"Rushing"(they word) to nicotine patches and nicotine's substitutes.
whose price are re-embourses buy the government up to 150 Euro per year.
Again Esad thanks for posting and thanks for your valuable contribution and opinion on this board.
After reading this article, there is no going back..Gottlieb said enough..
The pressure is mounting and the cooker is about to explode...
Cheers!
Introducing "pot beer" that can get you high
Ceria Beverages, from Keith and Jodi Villa, are infused with THC. Get ready, world.
https://www.metro.us/lifestyle/food-and-drinks/pot-beer-ceria-beverages
Slow days here lately so here is a good read..
CBD is cannabis that won’t get you high. So why are so many people using it?
https://www.washingtonpost.com/lifestyle/style/cbd-is-cannabis-that-wont-get-you-high-so-why-are-so-many-people-using-it/2018/03/29/3836922a-2d2c-11e8-8ad6-fbc50284fce8_story.html?utm_term=.98e3b93eeb8a
Skype.. Thanks for posting..
It's coming.......Just have to be patient.
Scott Gottlieb this morning on CNBC
I was too busy to watch but just caught those lines..
1)Potentiel move coming on regulating E cigarettes.
2) white house supporting FDA on Tabaco reform.
Scott Gottlieb this morning on CNBC
Will address Tabaco regulation at the on going health conference today.
Also said it will be a long and complicated road regarding reforming legislation and political .
Tomorrow Scott Gottlieb, M.D., U.S. FDA Commissioner of Food and Drugs
on CNBS squawk box talking health care...
Will he talk about smoking??
CNBC to host inaugural one-day conference for health care investors, innovators and executives on March 28th in NYC
Interview with FDA Commissioner of Food and Drugs Scott Gottlieb to open conference
ENGLEWOOD CLIFFS, N.J., February 15, 2018 —CNBC today revealed their speaker lineup ahead of its first-ever business of health care conference, Healthy Returns, which will take place on March 28th, 2018 at The Roosevelt Hotel in NYC.
With the help of the previously announced world-class advisory board, discussions will explore investment ideas and insights from the biggest and best health care investors, strategic perspectives from top health care CEOs, an early inside look at transformative innovations, and more. Opportunities for networking will be available throughout the course of the day.
The conference's speaker lineup comprises some of the most innovative medical technologists, entrepreneurs, executives and investors representing the biotech, pharma, health care and life sciences industries, including:
Amy Abernethy, M.D., Ph.D., Chief Medical Officer and SVP, Flatiron Health
Katrine Bosley, CEO, Editas Medicine
Abbie Celniker, Ph.D., Partner, Third Rock Ventures
Tony Coles, M.D., Chairman and CEO, Yumanity Therapeutics
David Cordani, President and CEO, Cigna
Delos 'Toby' Cosgrove, M.D., former President and CEO, The Cleveland Clinic
Alex Denner, Ph.D., Founding Partner and CIO, Sarissa Capital Management
Esther Dyson, Executive Founder, Way to Wellville; Board Member, 23andMe and Open Humans Foundation
Bill George, Senior Fellow, Harvard Business School; former Chairman and CEO, Medtronic
Scott Gottlieb, M.D., U.S. FDA Commissioner of Food and Drugs
Andrew Farnum, Director of Program-Related Investments, Bill & Melinda Gates Foundation
Fred Hassan, Special Limited Partner, Warburg Pincus; Chairman, Caret Group; former Chairman and CEO, Schering-Plough
Jeff Jonas, M.D., CEO, SAGE Therapeutics
Iyah Romm, Co-Founder and CEO, Cityblock Health
Jessica L. Mega, M.D., M.P.H., Chief Medical Officer, Verily Life Sciences
Mike Moore, Partner, Mike Moore Law Firm; former Attorney General, State of Mississippi
Christopher O'Connor, Partner, Perella Weinberg Partners
Leonard S. Schleifer, M.D., Ph.D., Founder, President and CEO, Regeneron Pharmaceuticals
Todd B. Sisitsky, Managing Partner, TPG Capital
Robin Thurston, CEO, Helix
J. Craig Venter, Ph.D., Co-Founder, Executive Chairman and CEO, Human Longevity; Founder, Executive Chairman and CEO, J. Craig Venter Institute
Sponsors for the event include Change Healthcare and Hospital for Special Surgery. The initial agenda, including the speaker lineup and session times and topics, will be available in the coming days.
Why hasn't the FDA released the data on the Phase III trial of 1250 people that was concluded on March 2017?
To give everybody time to accumulate shares at a basement price..?? :)
But more seriously .. it is puzzling and only the FDA knows the answer to that Q and maybe XXII too??
Are they still working on the East River Drive???
They are still working on the entire city for the past what? 100 years??lol
New-York city is and has always been a work in progress, it never stops !
I love it, I hate it, moved out 3 times but always came back !
Go XXII so I can finally buy my apartment!
"Sunnyside, are now teeming with great restaurants and new buildings".
Agree :) I have been living in Sunnyside (Queens) for 20 years now after living in the lower east side for about 10 years .Sunnyside has changed so much (for the best), lot of new and great restaurants in the past few years, Lot of people moving in and escaping the city High rent and yes craziness and noise.
I live by Sunnyside gardens, only 2 blocks from the subway 7 train and only about 15 minutes to Midtown. will never move back to the city, even if I could afford it. only problem now is rent here has been going up big time but still half of what it is in the city.
Sunnyside, a small town in the big city!
You should come and visit :)
I for one wouldn't mind if it passes.........
Proposed bill would ban smoking while walking in NYC
By NY1 News | March 22, 2018
It's illegal in restaurants, bars and stores. And soon, smoking cigarettes could be banned on city sidewalks, too.
That's if Queens City Councilmember Peter Koo gets his way. He has introduced legislation banning smoking while walking.
"Too many times, when we are walking, we get stuck behind somebody with smoke, and you have to inhale all the secondhand smoke, and it's terrible for your health," Koo said.
The ban also would apply to smokers walking along street medians and public plazas. However, simply standing outside and smoking would still be OK.
The bill only targets smokers who walk because they subject other pedestrians to secondhand smoke.
Some New Yorkers back the proposal.
"That's defintely a step in the right direction," said one New Yorker. "Even with parks and open spaces, they started that ban, and it seemed to work well. I mean, people were annoyed at first, but everyone just gets used to it, and it becomes the new normal, and then, eventually, you'll see a dramatic decrease in smoking."
Others, though, say the legislation goes too far given how few places are left in the city for smokers to legally light up.
"Well, I think smoking is bad for you and for the public, but if people want to smoke in public streets, I don't think that that's necessarily a bad thing," said one New Yorker.
"I think it's not a good ban because it's eliminating people's right to smoke. They're getting boxed into a corner a little bit right now," said another. "It's a little bit of a precious law, and I don't think anyone could observe it. How could you ever enforce something like that?"
The city banned smoking in bars and restaurants in 2003, and in parks and beaches in 2011.
Koo says those caught smoking and strolling would be fined $50, the same penalty for park puffers.
"We all share the same sidewalks, the public spaces, so we hope that they can give us the courtesy. When they want to smoke, they smoke standing in a corner, so when we see them, we can bypass them," he said.
After the bill is officially proposed Thursday, it will be sent to a council committee for a public hearing, where it eventually will face a vote or go up in smoke.
http://www.ny1.com/nyc/all-boroughs/news/2018/03/21/smoking-while-walking-bill
Well They could try to fight it, not sure on what ground tho since they are basically killing people.
or try to delay the process but I am sure the FDA will mandate a period of time so they can adjust and prepare .
But one Q is if the FDA mandate low nicotine in the US, that doesn't prevent the big T to sell their regular cigarettes around the world..
....Unless the world follows the US.
Remember in France the price of a pack of cigarette is around $10 and 80 % of that price is tax only ! big money going into the government pocket.Now the cost for the government for treating smoking illnesses and cancer is also huge. They are actually increasing the tax on tobacco products to pay for part of the healthcare cost due to smoking.
Well you eliminate/lower nicotine = you eliminate/lower health care cost and save million of life, a no brainer..
All it's gonna take is ONLY ONE COUNTRY to go with very low nicotine cigarettes and the rest of the world will follow.. no choice they will have to...
........................................................................
If the FDA mandates all cigarettes must contain less than .04 milligrams of nicotine, which they consider non-addictive, what will big tobacco do???
With the exception of the QTP patent family that will expire in 2018, the majority of our patent families related to nicotine biosynthesis will expire between 2021 and 2034
2021 is round the corner Do you think big T will drag their feet and try to sue just to gain time until some patents expire ...
just thinking out loud
FDA Time is of the essence !!
Thanks Skype, I thought that's what I did but after reviewing my post it was still black.
......................................................................
tip: first you should Highlight the text you want to appear in red, then click 'Color' on the left panel of actions.
Well after reading it my take is.....
#1 it is a long and complicated process.
#2 it is not accurate.
#3 they will have to use ONLY this type of tobacco.
#4 Their lowest nicotine level is (Burley tobacco leaves (0.650 %).)
Our SPECTRUM [research] cigarettes that contain 0.4 mg nicotine/gram (g) of tobacco filler."(But not sure if it is a good comparaison)
#5 Moreover atmospheric conditions such as temperature, rainfall, humidity of the cultivation area, cultural practice of cultivation and maturity level contribute significant difference on nicotine levels of the tobacco leaves of the two places
And then their conclusion..
The level of nicotine in the Ethiopian tobacco leaves were determined by high performance liquid chromatography. The analysis of tobacco leaves was based on their leaf positions, places of cultivation and variety of species. Among the variety of species Virginia tobacco leaves were found to have high nicotine level (3.26 %), followed by the native tobacco ‘Gaya’ (1.11 %) then Burley tobacco leaves (0.650 %). The nicotine level in Oriental tobacco leaves was below the detection limit and its’ accurate level of nicotine was not determined by this study. Based on their leaf positions, the nicotine level of Ethiopian Virginia tobacco leaves like that of other countries increases from bottom to top (tip) leaves. Furthermore this study has found that nicotine level of a given tobacco species cultivated in different places is different. The levels of nicotine in Ethiopian tobacco leaves are comparable with that cultivated in the rest of world
I am still gonna put my bet on XXII
................................................................
Levels of nicotine in Ethiopian tobacco leaves - NCBI - NIH
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4628019/
by Z Tassew - ?2015 - ?Cited by 3 - ?Related articles
Oct 29, 2015 - It was found that the nicotine level of Ethiopian Virginia tobacco leaves increases from bottom to top leaf (stalk) positions of the tobacco plant. ... The majority of the tobaccos entering the world trade are produced in tropical and temperate regions, i.e. almost all continents are capable of growing tobacco, and ...
4 Stocks To Watch Following The FDA's Proposal To Lower Nicotine In Cigarettes
Today 10:09 AM ET (Benzinga)Print
What Happened
The U.S. Food and Drug Administration announced March 15 an Advance Notice of Proposed Rulemaking (ANPRM) to procure information to help set the maximum nicotine level for cigarettes to non-addictive levels.
22nd Century Group Inc (NYSE: XXII), Philip Morris International Inc. (NYSE: PM), Altria Group Inc (NYSE: MO) and British American Tobacco PLC (ADR) (NYSE: BTI) all traded lower following the announcement.
Why It’s Important
The reduction of nicotine to non-addictive levels is meant to cut smoking frequency in the U.S.
“This could give addicted users the choice and ability to quit more easily, and it could help to prevent experimenters (mainly youth) from initiating regular use and becoming regular smokers,” according to the notice.
Cigarette manufacturers are expected to suffer sales reductions as the FDA pursues its goal.
What’s Next
The FDA will accept relevant scientific data and research as well as comments regarding the scope of products regulated under the new standards in the ANPRM. All comments are due June 14.
"With ownership or control of patents on the genes in the tobacco plant that regulate nicotine production, 22nd Century is able to grow tobacco with up to 97% less nicotine than tobacco used in conventional cigarettes," the company said in a Monday press release.
22nd Century was the only one of the aforementioned stocks to trade in positive territory Monday morning at time of publication.[color=red][/color]
Agree
I don't care how many gazillion patents BTI or other companies have, they don't have the ONLY ONE that matter! only XXII has it ! and if prior art existed before, those patents would have NEVER been issued to XXII on the first place..
Long XXII
So all we need to find out is if any of the BT had any prior arts in trying to lower nicotine or in XXII case lowering nicotine level in cigarettes thru genetic engineering??
I scanned it quickly but the entire document (100 pages) is worth reading...I am sure a couple of people here will dissect the document..
Here are the part XXII is mentioned by name...
Researchers also have used Quest cigarettes, produced by Vector Tobacco, to study the
impact of reduced nicotine (Ref. 76). To provide consumers with reduced risk tobacco products,
companies like 22nd Century are using genetic engineering and plant breeding to produce very
low nicotine tobacco for incorporation into cigarettes. In 2014, the company was granted patents
for its process to virtually eliminate the nicotine in tobacco plants (Ref. 77). Further, low
nicotine cigarettes are produced and distributed for research purposes by Research Triangle
Institute (RTI), under a contract for the NIDA’s Drug Supply Program (Ref. 78). 22nd Century
is acting as a vendor for RTI for this contract manufacturing Spectrum cigarettes that contain 0.4
mg nicotine/gram (g) of tobacco filler (id). Finally, Philip Morris manufactured cigarettes with
varying nicotine levels for research only (Ref. 79). FDA requests data and information regarding
the risks to smokers from inhalation of VLNC cigarette smoke.
Table 1 includes a list of VLNC cigarettes used in research studies and their reported
nicotine levels.
Table 1.--Filler Nicotine and ISO Nicotine Delivery for Low and Very Low (*) Nicotine Cigarettes Made Available Either Commercially or for Research Type of Cigarette Filler Nicotine Level (mg/g or mg/cig) ISO Nicotine Delivery (mg/cig) Quest 1 12.5 mg/g; 8.9 mg/cig 0.6 Quest 2 6.4 mg/g; 5.1 mg/cig 0.3 Quest 3 1.0 mg/g; 0.4 mg/cig 0.5*
9 Both Ultratech and Lifetech have been reported as being the company through which NIDA manufactured research cigarettes.
37
As previously described, VLNC cigarettes have been produced since the 1970s. During
this time, NCI contracted for production of a line of cigarettes with widely varying nicotine
concentrations (Ref. 122, 81 SG). In the late 1980s, a major cigarette manufacturer had plans to
develop VLNC cigarettes with a reduction in mainstream nicotine yields of greater than 95
percent (Ref. 123). More recently, 22nd Century, acting as vendor for RTI’s contract with
NIDA, has developed cigarettes, not currently commercially available, that are similar in many
sensory characteristics to conventional cigarettes but with extremely low nicotine levels (Refs.
54, 124, and 125).
51
Significant reductions of nicotine in combusted tobacco products can be achieved
principally through tobacco blending and cross-breeding plants, genetic engineering, and
chemical extraction. Agricultural practices (e.g., controlled growing conditions, fertilization,
harvest) as well as more recent, novel techniques also can help to reduce nicotine levels. One or
a combination of these processes could be used to achieve the nicotine levels that FDA is
considering for a nicotine tobacco product standard.
https://s3.amazonaws.com/public-inspection.federalregister.gov/2018-05345.pdf
Thanks for that article,
It put definitely things into perspective .
I think the FDA is on our side, after all they said about lowering the nicotine content in cigarettes there is no backing up, otherwise they will look like accomplice to the thousand of people dying every year from cancer. knowing that everybody knows now and is aware there is a solution and the means to lower or get rid of the nicotine in tobacco they have to go forward, but it may take more time than we expect.
My only concern and as you state it is big tobacco won't give up without a fight. I know you can not compare it to what is going on in Florida right now, with the NRA suing the state for passing a anti gun law.
but the NRA have the second amendment on their side. Big tobacco doesn't have anything...
"The big question...is the FDA on our side? Big tobacco is not going to roll over unless there is something in it for them"
The writing is on the wall! All over the wall!!
Long XXII
Just found this new website
https://www.shortpainbot.com/?s=xxii
Esad your comment
"China sales are a guess as no western cigarette companies sell there."
Pique my curiosity and did a little research , very interesting reading into the Chinese smoking world
"The ALL article is a good read but here is the conclusion"
Anti-Smoking Attitudes
Although China might still be behind much of the world in reducing the health risks associated with smoking, the last few years have seen a sharp increase in public awareness of the dangers of cigarettes. A recent campaign, "The gift of cigarettes is the gift of cancer," graced billboards around the country. Cigarette companies are still banned from advertising on TV and in magazines.
Smoking is, in fact, banned in bars and restaurants across China. While enforcement at the moment is still extremely lax, more and more restaurants (especially upscale places) are asking smokers to step outside. Taxi drivers, too, will occasionally ask that their fares wait.
Although smoking is becoming less and less popular around the world, it looks like it'll have a place in Chinese society for years to come. Tobacco farmers are happy to have a consistent buyer in the China National Tobacco Corporation, which makes a tidy profit for the government. Most importantly, cigarettes are still an important way of making a statement in any number of social contexts.
https://cn.hujiang.com/new/p416893/
Great! Thanks ...Should be interesting ....
I think you will be safer with just lowering the amount of nicotine in cigarettes!!!
Also those cessation smoking programs still cost $$ to the health care NO?? since they are cover by insurances so the health care system will be saving lot of $$ if FDA goes with lowering nicotine content in cigarettes.
negative side effects can include nausea, vomiting, convulsions, heart pain, headache and, in larger doses, even death via respiratory failure.
Cytisine - Wikipedia
https://en.wikipedia.org/wiki/Cytisine
Also
Important Safety Information and Indication
When you try to quit smoking, with or without CHANTIX, you may have symptoms that may be due to nicotine withdrawal, including urge to smoke, depressed mood, trouble sleeping, irritability, frustration, anger, feeling anxious, difficulty concentrating, restlessness, decreased heart rate, and increased appetite or weight gain.
Some people have had new or worse mental health problems, such as changes in behavior or thinking, aggression, hostility, agitation, depressed mood, or suicidal thoughts or actions while taking or after stopping CHANTIX. These symptoms happened more often in people who had a history of mental health problems. Stop taking CHANTIX and call your healthcare provider right away if you, your family, or caregiver notice any of these symptoms. Before starting CHANTIX, tell your healthcare provider if you ever had depression or other mental health problems.
Some people have had seizures during treatment with CHANTIX. Tell your healthcare provider if you have a history of seizures. If you have a seizure, stop taking CHANTIX and contact your healthcare provider right away.
"$achv cites several large positive tests previuosly done on cytisine...so what will be so compelling about theirs, if equally successful...sounds like a retread of substance that has some value, but already to market".
Interesting development from another company I own shares in
Medical Marijuana, Inc. Major Investment AXIM Biotech Announces First-Ever Successful Achievement of Proprietary cGMP Extraction and Manufacturing Methods for Pure Cannabinoid Molecules
9:00 am ET February 28, 2018 (PR Newswire) Print
Medical Marijuana, Inc. (OTC: MJNA), the first-ever publicly traded cannabis company in the United States, announced that its major investment company AXIM(R) Biotechnologies (OTC:AXIM) ("AXIM") has successfully executed their first-ever proprietary current good manufacturing practices ("cGMP") methodology in the extraction and microencapsulation of cannabinoid molecules for a variety of pharmaceutical delivery formats from cGMP-produced medicinal cannabis.
The breakthrough makes AXIM the only Company in the world with the ability to harness the proprietary procedure and provide Active Pharmaceutical Ingredients ("APIs") of such purity from naturally extracted cGMP sources.
"We're proud to see AXIM Biotech continue to be a pioneer in cannabinoid research," said Medical Marijuana, Inc. CEO Dr. Stuart Titus. "We hope that this new extraction process will expand the pharmaceutical cannabinoid market and broaden the potential areas of application."
AXIM's new methods are unprecedented in terms of the nature of the process - which utilizes cGMP standards employed from the initial growing of the cannabis plants through extraction and manufacturing - leading to the highest of quality standards for APIs being met.
The process, which was developed and tested in the Netherlands under strict regulatory guidelines, involves the growing of selected cannabis plants at a cGMP facility followed by extraction of the cannabinoid molecules from cannabis flowers in an innovative process that employs just two steps in order to achieve an average of more than 99% purity - unlike traditional methods that include toxic solvents and multiple steps to produce the final extract or synthesize an API such as dronabinol.
AXIM's newly developed microencapsulation method is then applied to the cannabinoids, protecting those from oxidation and degradation, while preserving its effectiveness. Finally, AXIM's microencapsulated cannabinoids are manufactured into pharmaceutical products within different delivery formats.
About Medical Marijuana, Inc.
We are a company of firsts(R). Our mission is to be the premier cannabis and hemp industry innovators, leveraging our team of professionals to source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit. We strive to create awareness within our industry, develop environmentally-friendly, economically sustainable businesses, while increasing shareholder value. For details on Medical Marijuana, Inc.'s portfolio and investment companies, visit www.medicalmarijuanainc.com.
To see Medical Marijuana, Inc.'s corporate video, click here.
Shareholders and consumers are also encouraged to buy CBD oil and other products at Medical Marijuana, Inc.'s shop.
ABOUT AXIM
AXIM(R) Biotechnologies, Inc. ( AXIM ) focuses on the research, development and production of cannabinoid-based pharmaceutical, nutraceutical and cosmetic products. Our flagship products include CanChew+(R)a CBD-based controlled release chewing gum, CanChew+ 50(R), containing 50 mg of CBD undergoing clinical trials in patients with IBS and MedChew Rx(R), a combination CBD/THC gum that will undergo clinical trials for the treatment of pain and spasticity associated with multiple sclerosis. AXIM has several products developed or in developmental stage for treatment and/ or prevention of multiple conditions and symptoms. We prioritize the well-being of our customers while embracing a solid fiscal strategy. For more information, please visit AXIMBiotech.co
They ran this stock as low as they could, below the 200MA at 2.37 and now back on our way up slowly, while the Dow jones is down 240 points .
Great ! well hopefully their $$ is moving into XXII! :)
"BTI..52 week low..Mo...close to 52 week low...PM...heading that way...I think big institutions are realizing the FDA is serious..
The management of those companies are going to sober up and make a deal with us..."
Great info thanks!
Just to reaffirm where we are going and reconfirm what we know with XXII technology ..
Now it is not a matter of IF but WHEN !
Go XXII !!
ALWAYS NICE TO BE MENTIONNED...
Biotech's Combating Cardiovascular Diseases with New Technology
Today 10:30 AM ET (PR NewsWire)Print
FN Media Group Presents Microcapspeculators.com News Commentary
Despite significant technological advances in technology, cardiovascular diseases (CVDs) remain the number one cause of death globally. CVDs are a group of disorders of both the heart and blood vessels that can lead to heart attacks and strokes. The history of treatment for CVDs is extensive, but as we move forward in medical research, three distinctive treatments are truly changing lives. Included in today's commentary: Endonovo Therapeutics, Inc. (OTC: ENDV), 22nd Century Group, Inc. (NYSE: XXII), Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), Emerald Health Therapeutics, Inc. (TSX-V: EMH) (OTC: EMHTF), Delcath Systems, Inc. (OTC: DCTH)
The first is a new treatment for high cholesterol, a drug therapy called PSCK9 inhibitor. This inhibitor has been shown to reduce bad cholesterol (LDL-C) by as much as 50 to 70 percent with little negative effects. This has proved to be helpful for patients who cannot take statins because of horrible adverse effects.
Congestive heart failure is a common disorder characterized by a failure of the heart muscle to forcefully pump blood to the body's tissues. Patients often suffer from severe shortness of breath and a low quality of life. The second treatment giving hope for patients is a drug by the name of LCZ696 and proves to be highly effective in clinical trials. It achieved a substantial 20 percent reduction in death or repeat hospitalization compared with the best currently available therapies.
The third and most innovative therapy are non-invasive medical devices called Electroceuticals that deliver electrical pulses to inflamed tissues like the heart following a heart attack. Most CVDs are caused by atherosclerosis, a disease process that causes thickening of the arterial wall because of inflammation and lipid accumulation, resulting in plaque formation. Electroceuticals target the underlying issue of CVDs: inflammation and restricted blood flow. This technology can be used across medical issues as it targets inflammation, an underlying component of many diseases like chronic kidney failure, non-alcoholic steatohepatitis (NASH), stroke and diabetes.
It is through the development of new drugs and therapies that the biotech world hopes to change the outcome for patients suffering from CVDs, and lower its rank on the list as number one cause of death globally.
In other biotech news, check out Endonovo Therapeutics, Inc. (OTCQB: ENDV), 22nd Century Group, Inc. (XXII), Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), Emerald Health Therapeutics, Inc. (CVE: EMH) (OTCQX: EMHTF), and Lexington Biosciences, Inc.
Endonovo Therapeutics, Inc. (OTCQB: ENDV)
Market Cap: $14.195M, current share price: $.0465
Endonovo's FDA-Cleared and CE Marked non-invasive medical device, SofPulse(TM), delivers Electroceutical(TM) therapy to reduce pain and post-surgical swelling. ENDV's SofPulse(TM) also has CMS National Coverage (Medicare reimbursement) for the treatment of chronic wounds. SofPulse(TM) aims to reduce the dependency on narcotics following surgeries, such as breast augmentation surgery, by reducing the underlying cause of the pain itself: inflammation. Clinical trials on SofPulse(TM) have shown a 57% reduction in pain at one hour post breast augmentation surgery, a 300% reduction in pain at 5 hours post surgery, and a 2.2-fold reduction in narcotics use. Furthermore, ENDV is developing its Electroceutical(TM) therapy for the treatment of cerebrovascular and cardiovascular diseases, which have an underlying inflammatory component. With clinical data showing improvements in SAQ scores for angina severity and physical capacity in patients with end-stage ischemic heart disease and failed medical therapy and revascularization options ("no option" patients), Endonovo Therapeutics, Inc. (ENDV) is severely undervalued compared to its peers, such as Pulse Biosciences and Helius Medical Technologies, and is worth multiples of today's prices.
22nd Century Group, Inc. (NYSE: XXII)
Market Cap: $341.074M, current share price: $2.760
The plant biotechnology company XXII focuses on tobacco harm reduction and hemp/cannabis research. The FDA announced big plans in 2017 to limit nicotine in cigarettes to minimally or non-addictive levels which caused further research published in early 2018 by The National Academies of Sciences, Engineering, and Medicine (NASEM) evaluating the available scientific evidence addressing the short- and long-term health effects related to the use of electronic nicotine delivery systems (ENDS). James E. Swauger, Sr. VP of Sciences and Regulatory Affairs for XXII believes that the Company's Very Low Nicotine tobacco technology demonstrates that the FDA's plan to dramatically reduce nicotine in cigarettes is technologically feasible.
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP)
Market Cap: $443.799M, current share price: $7.9815
The clinical-stage drug development company, CRBP, targeting rare, chronic, serious inflammatory and fibrotic diseases announced their CEO, Yuval Cohen, Ph.D., will be presenting tomorrow, February 22nd at the 2018 RBC Capital Markets Global Healthcare Conference. Dr. Cohen will present at 3:35pm EST and will be discussing Company's four clinical development programs. A live au
COPY :)
22nd Century Group to Present International Survey Findings at the Society for Research on Nicotine and Tobacco Annual Meeting
Today 9:15 AM ET (Business Wire)Print
22nd Century Group, Inc. (NYSE American: XXII), a plant biotechnology company focused on tobacco harm reduction, will present at the 2018 Society for Research on Nicotine and Tobacco (SRNT) Annual Meeting results from a survey conducted by Harris Poll on behalf of 22nd Century Group. In May 2017, 22nd Century commissioned Harris Poll to administer the international survey of more than 6,000 adults ages 18 and older in the United States, Australia, Canada, Japan, and the United Kingdom.
This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180222005454/en/
Conducted two months before the U.S. Food and Drug Administration (FDA) announced the Agency's plan to mandate that all cigarettes sold in the United States contain only minimally or non-addictive levels of nicotine, the survey found that nearly 3 of every 4 adults in the United States, Japan, Australia, Canada, and the United Kingdom agree that the government should mandate that all cigarettes have very low, non-addictive levels of nicotine. "We look forward to sharing this information with the international scientists and researchers attending SRNT," explained James Swauger, Ph.D., Senior Vice President of Science and Regulatory Affairs at 22nd Century Group.
Results from the 22nd Century Group survey are consistent with other independent reports on the subject. Research published January 5, 2018 in the International Journal of Environmental Research and Public Health also reported broad public support for government-mandated reductions of nicotine content in cigarettes. Conducted by Allison M. Schmidt, et al, the study, "Attitudes towards Potential New Tobacco Control Regulations" reviewed data from a nationally representative telephone survey that was conducted in 2015 and was administered by the Center for Regulatory Research on Tobacco Communication (CRRTC). The survey found that 71% of 4,337 adults surveyed in the U.S. support an FDA policy requiring "companies to reduce nicotine in cigarettes." Explaining the importance of their results, Schmidt, et al. point out: "Favorable attitudes toward tobacco control policies can contribute to policy adoption, effective implementation, and success in changing tobacco-related attitudes and behaviors."
While stakeholders in the public health community, the regulatory community, and the tobacco industry will actively participate in the regulatory process, the public is far less likely to participate or to be represented in this discussion. On this point, Dr. Swauger noted, "We believe survey-based research - specifically addressing government-mandated nicotine reductions in cigarettes - represents an important means of developing an understanding of the public's view on this novel public health initiative."
Survey Methodology
22nd Century's survey was conducted online by Harris Poll from May 24-28, 2017 among 2,148 adults ages 18 and older in the United States; 1,014 adults ages 18 and older in the United Kingdom; 1,056 adults ages 18 and older in Japan; 1,050 adults ages 18 and older in Canada; and 1,033 adults ages 18 and older in Australia. This online survey is not based on a probability sample and therefore no estimate of theoretical sampling error can be calculated. For complete survey methodology, including weighting variables, please contact (716) 270-1523.
About 22nd Century Group, Inc.
Thanks
we know that , that is why it doesn't make sense what they are doing and saying.....
Skype You said Doesn't
"this imply (rightly or wrongly) that there could be other suppliers of VLN cigarettes with less than 0.4 mg of nicotine each?"
I had exactly the same thought, I thought XXII was the only company in the world capable of that by using its technology...
I am sure Canada is aware of XXII
Quote:
"VLN cigarettes, which have less than 0.4 mg of nicotine each, aren’t available in Canada now. The tender notice is meant to find out which companies could make them and at what cost."
Thanks for your input as usual.
There are so many variants on what can happen and what the FDA will decide ultimately and so many players in the game..The next few weeks , months should be very interesting.
Great video on understanding how nicotine works on you body.
and yes it would make sense to gradually reduce your nicotine intake if you want to quit smoking.
"this video which would seem to support the gradual reduction in nicotine approach"